Need professional-grade analysis? Visit stockanalysis.com
$1.20B
N/A
1,440
N/A
PolyPeptide Group AG (PPGN) trades on SIX Swiss Exchange in CHF. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at CHF36.25, down 0.55% from the previous close.
Over the past year, PPGN has traded between a low of CHF16.68 and a high of CHF37.50. The stock has gained 117.3% over this period. It is currently 117.3% above its 52-week low.
PolyPeptide Group AG has a market capitalization of $1.20B.
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Side-by-side comparison against top Healthcare peers.